China SXT Pharmaceuticals (SXTC) Cash & Equivalents (2017 - 2026)

China SXT Pharmaceuticals has reported Cash & Equivalents for 10 years, with the latest figure at $28.2 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 55.68% year-over-year to $28.2 million in Q1 2026; TTM through Mar 2026 was $28.2 million, a 55.68% increase from a year earlier, with the FY2026 full-year figure at $28.2 million, up 55.68% from the prior year.
• Cash & Equivalents was $28.2 million for Q1 2026 at China SXT Pharmaceuticals, up from $21.2 million in the prior quarter.
• The five-year high for Cash & Equivalents was $28.2 million in Q1 2026, with the low at $12.1 million in Q1 2024.
• Average Cash & Equivalents over 5 years is $18.0 million, with a median of $17.4 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents jumped 49609.84% in 2022, then tumbled 30.46% in 2024.
• Over 5 years, Cash & Equivalents stood at $15.6 million in 2022, then climbed by 11.55% to $17.4 million in 2023, then gained by 6.59% to $18.5 million in 2024, then advanced by 14.33% to $21.2 million in 2025, then jumped by 33.12% to $28.2 million in 2026.
• The last three Cash & Equivalents figures came in at $28.2 million (Q1 2026), $21.2 million (Q3 2025), and $18.1 million (Q1 2025), per Business Quant data.